Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Overview Between February and June 2026, twelve drugs previously rated by MARA received new regulatory approvals — from the FDA or EMA — triggering a formal surveillance reassessment of each
Overview MARA Rating completed 17 new Reimbursement Risk Assessments in June 2026. The assets span nine therapeutic areas: oncology, obesity, neurology, rare disease, pulmonology, cardiology, immunology, hepatology, and infectious disease.
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for
Executive Summary During May 2026, MARA issued 14 new rating actions across hepatology, oncology, neurology, immunology, psychiatry, infectious diseases, pediatrics, and gynecology. The distribution was concentrated in the middle reimbursement-risk
A MARA Rating we completed for an Alzheimer’s treatment arrived with one of the highest public profiles in recent memory. The phase 3 trial showed meaningful slowing of cognitive decline.
We have just published a MARA Rating for a maintenance treatment in lung cancer. The trial answered one question clearly: does this treatment extend survival? It does. Patients lived longer
In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
1. Executive Summary During April 2026, MARA issued 12 rating actions across multiple therapeutic areas. The monthly distribution was concentrated in B+ (Very Weak) and B++ (Marginal), with no A-range,
MARA rated sebetralstat (Ekterly) B++ (Marginal) before the G-BA published Beschluss 7763 on 2 April 2026. The G-BA recognized a non-quantifiable additional benefit under the orphan drug pathway — placing
MARA rated linvoseltamab (Lynozyfic) B+ (Very Weak) before the G-BA published Beschluss 7730 on 19 March 2026. The B+ signal was driven by two structurally weak decision-critical domains: no HRQoL